Valuation: BICO Group AB

Market Cap 1.54B 154M 136M 129M 116M 219M 14.81B 222M 593M 7.57B 580M 567M 24.28B P/E 2026 *
-6.79x
P/E 2027 * -12.2x
Enterprise Value 1.47B 148M 130M 123M 111M 209M 14.15B 212M 567M 7.23B 554M 542M 23.19B EV / Sales 2026 *
0.91x
EV / Sales 2027 * 0.82x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
1 day-4.80%
1 month+3.86%
3 months+22.02%
6 months+5.91%
Current year-12.60%
1 month 2.15
Extreme 2.15
2.26
Current year 1.52
Extreme 1.522
2.31
1 year 1.52
Extreme 1.522
2.73
3 years 1.52
Extreme 1.522
6.9
5 years 1.52
Extreme 1.522
60.45
10 years 0
Extreme 0
100
Manager TitleAgeSince
Chief Executive Officer 51 2026-08-31
Director of Finance/CFO 56 2026-02-28
Chief Operating Officer - 2026-01-06
Director TitleAgeSince
Director/Board Member 71 2019-12-17
Director/Board Member 37 2015-02-28
Director/Board Member - 2026-05-06
Change 5-day change 1-year change 3-year change Capi.($)
-4.80%-.--% - - 154M
-0.67%+1.47%+39.18%+33.36% 250B
-1.84%-0.00%+11.75%-10.70% 156B
-1.35%+2.09%-9.08%+39.12% 144B
-0.52%-2.17%-55.29%-17.33% 63.26B
-2.00%-0.58%+10.99%+24.60% 49.75B
-1.55%+4.23%+34.25%+54.10% 48.58B
-1.76%+2.07%-17.49%-20.90% 47.99B
+2.47%+5.43%-4.18%+40.30% 46.22B
-0.87%+4.47%+46.56%+60.24% 43.17B
Average -1.19%+2.27%+6.30%+22.53% 94.22B
Weighted average by Cap. -0.96%+2.37%+11.79%+21.81%

Financials

2026 *2027 *
Net sales 1.62B 162M 143M 136M 122M 231M 15.58B 234M 624M 7.96B 610M 597M 25.53B 1.69B 169M 149M 141M 127M 240M 16.19B 243M 649M 8.28B 634M 620M 26.53B
Net income -227M -22.74M -20.02M -18.97M -17.13M -32.28M -2.18B -32.7M -87.36M -1.11B -85.39M -83.53M -3.57B -126M -12.62M -11.12M -10.53M -9.51M -17.92M -1.21B -18.15M -48.49M -619M -47.4M -46.36M -1.98B
Net Debt -69M -6.91M -6.09M -5.77M -5.21M -9.81M -663M -9.94M -26.55M -339M -25.96M -25.39M -1.09B -166M -16.63M -14.64M -13.87M -12.53M -23.61M -1.59B -23.91M -63.88M -815M -62.44M -61.08M -2.61B
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
554
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
21.85SEK
Average target price
29.00SEK
Spread / Average Target
+32.72%

Quarterly revenue - Rate of surprise